NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/25/2024
Back to search
Official data from USPTO
NEURAMEDY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
05/25/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
10/06/2021
Registration date
04/25/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/25/2023
Last transaction
07/08/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
KR
Examiner
GILBERT, REBECCA
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the gray stylized word "NEURAMEDY" with a blue circle design to the left. Inside the blue circle is a design of an "N" comprised of two separate white angular curved lines.
Holders and representatives
Holders
Neuramedy Co., Ltd.
Representatives
Cindy L. Caditz Davis Wright Tremaine LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for human purposes for the treatment of Central Nervous System (CNS) diseases; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the prevention of diseases of the cardio-vascular system; ophthalmic preparations; allergy medications; pharmaceutical preparations for diagnosis of Central Nervous System (CNS) diseases; pharmaceutical preparations and substances with analgesic properties; ethical medicinal preparations for the treatment of Central Nervous System (CNS) diseases; therapeutic drugs and therapeutic agents for treating Central Nervous System (CNS) diseases; pharmaceutical preparations for the treatment of Parkinson's disease; plant extracts for pharmaceutical purposes; medicated lozenges for pharmaceutical purposes; pharmaceutical preparations for use in dermatology; ferments for pharmaceutical purposes; pharmaceutical agents affecting sensory organs; drugs for medical purposes for the treatment of Central Nervous System (CNS) diseases; pharmaceutical preparations for the treatment of Central Nervous System (CNS) diseases
Class 42
Research and development of vaccines and medicines; medical research in the field of crude drugs; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research services; medical and scientific researchclinical testing of medicines; pharmaceutical drug development services; consultancy pertaining to pharmacology; testing of pharmaceuticals; pharmaceutical product evaluation; medical laboratory services; scientific research services for medical purposes; scientific research in the field of medicine; scientific analysis and evaluation of medical product development; medical and pharmacological research services; scientific research in the fields of medicine/health and pharmacology; scientific research in the nature of conducting clinical trials for others; development of medical products
Publications
History of USPTO decisions and trademark events.
38 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/28/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/03/2023
FIMP
FINAL DISPOSITION PROCESSED
08/03/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/25/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/30/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/30/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/30/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/30/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/01/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/25/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/25/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/12/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/12/2023
GPNX
NOTIFICATION PROCESSED BY IB
02/07/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/07/2023
PUBO
PUBLISHED FOR OPPOSITION
02/07/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/18/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/18/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/18/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/05/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
01/05/2023
ALIE
ASSIGNED TO LIE
01/05/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/04/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
01/04/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/20/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/20/2022
RFNT
REFUSAL PROCESSED BY IB
08/23/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/02/2022
RFRR
REFUSAL PROCESSED BY MPU
08/02/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/13/2022
CNRT
NON-FINAL ACTION WRITTEN
07/12/2022
DOCK
ASSIGNED TO EXAMINER
07/12/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/16/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/12/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/11/2021
Continuous trademark protection
Get notified about every new filing that threatens NEURAMEDY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.